Molina Healthcare (MOH) Investor Day 2024 summary

Strategic direction and growth model

• Sustaining profitable growth is the core focus, with a plan to grow revenue to $52–$55 billion by 2027, targeting 11%–13% annual premium growth through a balanced mix of organic expansion, strategic initiatives, and M&A.

• Organic growth is targeted at 7%–9% annually, with 4% from acquisitions, resulting in 11%–13% total top-line growth; about half of $9–12B targeted premium growth for 2027 is already secured.

• Medicaid, Medicare, and Marketplace businesses are expected to grow at 7%–9%, 12%–14%, and 5% respectively, with Medicaid as the flagship and significant upside if enhanced subsidies are extended.

• Embedded earnings from contract wins and M&A provide a visible runway for future EPS growth, with $6 per share in backlog for 2025–2027, less than half to be realized in 2025.

• The company operates a diversified, government-sponsored managed care franchise across 21 states, with $38B in 2024 premium revenue and 5.7M members.

Financial guidance and capital allocation

• Adjusted EPS is projected to grow 13%–15% annually, supported by 2% accretion from share repurchases and disciplined capital deployment.

• Capital deployment prioritizes organic growth (25% allocation, 60% ROE), accretive acquisitions (50% allocation, ~30% ROE), and shareholder returns via buybacks.

• The company expects to have $4.5 billion in deployable capital for M&A by late 2025, with a robust pipeline and $1.4B of acquired revenue already announced.

• Operating leverage is driven by disciplined cost management, automation, and productivity improvements, with G&A expected to decline further and industry-leading medical cost management underpinning margin sustainability.

• Reserve strength and low leverage (1.4x EBITDA) support ongoing growth and financial flexibility.

Business environment and risk management

• The managed Medicaid, Medicare duals, and Marketplace segments are seen as high-growth, resilient markets with large addressable opportunities.

• Regulatory and political changes are viewed as marginal, not existential, with the company well-positioned to adapt to evolving policy landscapes.

• Diversified state portfolio and product synergy (Medicaid, Marketplace, D-SNP) de-risk rate and reprocurement cycles.

• The company’s disciplined RFP selection and strong proposal process have led to high win rates in new contracts.

• Centers of Excellence in behavioral health, pharmacy, and LTSS drive medical management and cost control across the enterprise.